Development and external validation of a prediction model for brain metastases in patients with metastatic breast cancer

Wu, Qian; Sun, Ming-Shuai; Liu, Yinhua; Ye, Jingming; Xu, Ling

doi:10.1007/s00432-023-05125-y

Cited by 5 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Research has been conducted to establish predictive models for patients with bladder cancer brain metastasis [20], breast cancer brain metastasis [21], and colorectal cancer brain metastasis [22] to predict the survival period of these patients. In the context of NSCLC-BMs, J.P. Agarwal and colleagues conducted survival prognosis for patients following WBRT [23].…”

Section: Predictive Modelmentioning

confidence: 99%

Prognostic factors in postoperative brain metastases derive from non-small cell lung cancer：a retrospective analysis

Chen,

Sun,

Yang

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Brain metastases are crucial in cancer progression, requiring focused efforts on the screening, early detection, and treatment. However, accurately forecasting the postoperative prognosis of patients with non-small cell lung cancer brain metastasis remains a challenge. This retrospective study aims to discern the factors that influence the prognosis of such patients. Patients and materials: A total of 151 cases from Zhejiang Cancer Hospital were collected. Univariate analysis was conducted using Kaplan-Meier and Log-rank test, while multivariate analysis was performed using Cox proportional hazards regression model. Student’s t-test and chi-square test were employed to examine the differences between the long-term survival and the short-term survival groups. Ultimately, a predictive model was constructed by using R 4.2.1. Results: Univariate analysis identified 12 factors as prognostic factors, showing statistical significance. In multivariate analysis, the primary contributing factors to survival were identified as age, chemotherapy of brain metastases, pathology, surgery of non-small cell lung cancer, targeted drugs, and GPA score. Compared long-term and short-term groups, age, pathology, surgery of lung, targeted therapy, and radiotherapy of brain metastases were statistically differentiating factors. Based on multivariate analysis, we established a clinical predictive model predicting 2-year, 3-year, and 5-year survival rates. Conclusion: Younger age, receiving chemotherapy for brain metastases, adenocarcinoma pathology, lung cancer surgery, targeted therapy, and a high GPA score are associated with longer survival. This model predicts the survival period for patients with non-small cell lung cancer brain metastasis after surgery and helps in selecting more effective treatment plans.

show abstract

Section: Predictive Modelmentioning

confidence: 99%

Prognostic factors in postoperative brain metastases derive from non-small cell lung cancer：a retrospective analysis

Chen,

Sun,

Yang

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Metastatic brain tumors: from development to cutting‐edge treatment

Tanzhu,

Chen,

Ning

et al. 2024

MedComm

View full text Add to dashboard Cite

Metastatic brain tumors, also called brain metastasis (BM), represent a challenging complication of advanced tumors. Tumors that commonly metastasize to the brain include lung cancer and breast cancer. In recent years, the prognosis for BM patients has improved, and significant advancements have been made in both clinical and preclinical research. This review focuses on BM originating from lung cancer and breast cancer. We briefly overview the history and epidemiology of BM, as well as the current diagnostic and treatment paradigms. Additionally, we summarize multiomics evidence on the mechanisms of tumor occurrence and development in the era of artificial intelligence and discuss the role of the tumor microenvironment. Preclinically, we introduce the establishment of BM models, detailed molecular mechanisms, and cutting‐edge treatment methods. BM is primarily treated with a comprehensive approach, including local treatments such as surgery and radiotherapy. For lung cancer, targeted therapy and immunotherapy have shown efficacy, while in breast cancer, monoclonal antibodies, tyrosine kinase inhibitors, and antibody–drug conjugates are effective in BM. Multiomics approaches assist in clinical diagnosis and treatment, revealing the complex mechanisms of BM. Moreover, preclinical agents often need to cross the blood–brain barrier to achieve high intracranial concentrations, including small‐molecule inhibitors, nanoparticles, and peptide drugs. Addressing BM is imperative.

show abstract

Prognostic Factors in Postoperative Brain Metastases Derive From Non-small Cell Lung Cancer: A Retrospective Analysis

Chen,

Sun,

Yang

et al. 2024

Clin Med Insights Oncol

View full text Add to dashboard Cite

Background: Brain metastases are crucial in cancer progression, requiring focused efforts on the screening, early detection, and treatment. However, accurate forecasting the postoperative prognosis of patients with non-small cell lung cancer brain metastasis remains a challenge. This retrospective study aims to discern the factors that influence the prognosis of such patients. Methods: A total of 151 cases from Zhejiang Cancer Hospital were collected. Univariate analysis was conducted using Kaplan-Meier and Log-rank test, while multivariate analysis was performed using Cox proportional hazards regression model. Student’s t-test and chi-square test were employed to examine the differences between the long-term survival and the short-term survival groups. Ultimately, a predictive model was constructed using R 4.2.1. Results: Univariate analysis identified 12 factors as prognostic factors, showing statistical significance. In multivariate analysis, the primary contributing factors to survival were identified as age, chemotherapy of brain metastases, pathology, surgery of nonsmall cell lung cancer, targeted drugs, and GPA score. Comparing long-term and short-term groups, age, pathology, surgery of lung, targeted therapy, and radiotherapy of brain metastases were statistically differentiating factors. Based on multivariate analysis, we established a clinical predictive model predicting 2-year, 3-year, and 5-year survival rates. Conclusion: Younger age, receiving chemotherapy for brain metastases, adenocarcinoma pathology, lung cancer surgery, targeted therapy, and a high GPA score are associated with longer survival. This model predicts the survival period for patients with non-small cell lung cancer brain metastasis after surgery and helps in selecting more effective treatment plans.

show abstract

Development and external validation of a prediction model for brain metastases in patients with metastatic breast cancer

Cited by 5 publications

References 39 publications

Prognostic factors in postoperative brain metastases derive from non-small cell lung cancer：a retrospective analysis

Prognostic factors in postoperative brain metastases derive from non-small cell lung cancer：a retrospective analysis

Metastatic brain tumors: from development to cutting‐edge treatment

Prognostic Factors in Postoperative Brain Metastases Derive From Non-small Cell Lung Cancer: A Retrospective Analysis

Contact Info

Product

Resources

About